Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11200499rdf:typepubmed:Citationlld:pubmed
pubmed-article:11200499lifeskim:mentionsumls-concept:C0079904lld:lifeskim
pubmed-article:11200499lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:11200499lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11200499lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:11200499pubmed:issue4lld:pubmed
pubmed-article:11200499pubmed:dateCreated2001-1-26lld:pubmed
pubmed-article:11200499pubmed:abstractTextNuclear factor (NF)-kappaB is a transcription factor that induces the immunoglobulin kappa chain, cytokines such as interleukin (IL)-1, IL-2, IL-6, IL-8, tumor necrosis factor (TNF)-alpha and interferon gamma, and cell adhesion proteins. It also induces anti-apoptotic proteins, and inhibits TNF-alpha and anticancer drug-induced apoptosis. Therefore, NF-kappaB function inhibitors may be useful as anti-inflammatory and anticancer agents. Microbial products such as panepoxydone, cycloepoxydon and gliotoxin are known to inhibit activation of NF-kappaB. We have designed and synthesized new NF-kappaB inhibitors from the structure of an antibiotic, epoxyquinomicin C. The designed compound, DHM2EQ, inhibited TNF-alpha-induced activation of NF-kappaB and showed a therapeutic effect in mouse rheumatoid arthritis model.lld:pubmed
pubmed-article:11200499pubmed:languageenglld:pubmed
pubmed-article:11200499pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11200499pubmed:citationSubsetIMlld:pubmed
pubmed-article:11200499pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11200499pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11200499pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11200499pubmed:statusMEDLINElld:pubmed
pubmed-article:11200499pubmed:monthAuglld:pubmed
pubmed-article:11200499pubmed:issn0266-9536lld:pubmed
pubmed-article:11200499pubmed:authorpubmed-author:MatsumotoNNlld:pubmed
pubmed-article:11200499pubmed:authorpubmed-author:UmezawaKKlld:pubmed
pubmed-article:11200499pubmed:authorpubmed-author:ArigaAAlld:pubmed
pubmed-article:11200499pubmed:issnTypePrintlld:pubmed
pubmed-article:11200499pubmed:volume15lld:pubmed
pubmed-article:11200499pubmed:ownerNLMlld:pubmed
pubmed-article:11200499pubmed:authorsCompleteYlld:pubmed
pubmed-article:11200499pubmed:pagination239-44lld:pubmed
pubmed-article:11200499pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:11200499pubmed:meshHeadingpubmed-meshheading:11200499...lld:pubmed
pubmed-article:11200499pubmed:meshHeadingpubmed-meshheading:11200499...lld:pubmed
pubmed-article:11200499pubmed:meshHeadingpubmed-meshheading:11200499...lld:pubmed
pubmed-article:11200499pubmed:meshHeadingpubmed-meshheading:11200499...lld:pubmed
pubmed-article:11200499pubmed:meshHeadingpubmed-meshheading:11200499...lld:pubmed
pubmed-article:11200499pubmed:meshHeadingpubmed-meshheading:11200499...lld:pubmed
pubmed-article:11200499pubmed:meshHeadingpubmed-meshheading:11200499...lld:pubmed
pubmed-article:11200499pubmed:year2000lld:pubmed
pubmed-article:11200499pubmed:articleTitleNaturally occurring and synthetic inhibitors of NF-kappaB functions.lld:pubmed
pubmed-article:11200499pubmed:affiliationDepartment of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan. umezawa@applc.keio.ac.jplld:pubmed
pubmed-article:11200499pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11200499pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11200499lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11200499lld:pubmed